Press Release - NHRI Communications

A Novel Chemotherapy Regimen (SLOG) in Metastatic Pancreatic Cancer with Promising Efficacies
─NHRI has established a novel chemotherapy regimen, SLOG, with promising activity and safety profiles in the treatment of metastatic pancreatic cancer ─

PB November 30, 2020 November 30, 2020Press Release

November 30, 2020 Pancreatic ductal adenocarcinoma (PDAC) is a highly fatal malignant disease. Nearly 80–85% of patients presented with locally advanced or metastatic diseases at the time of diagnosis, and the overall 5-year survival rate is about 8% globally. Systemic chemotherapy is the standard of care for patients with unresectable…

A Safer Opioid Painkiller with Low Side-Effects
─NHRI has discovered a series of opioid receptor/nociception receptor dual agonists with fast and potent antinociception, fewer side-effects than morphine ─

PB November 23, 2020 November 23, 2020Press Release

November 23, 2020 The Ministry of Science and Technology has presented its 2020 Future Tech Breakthrough Award (Heterocyclic compounds and use thereof) to the National Health Research Institutes (NHRI) for the discovery of painkilling compounds that are safer and have fewer side effects than morphine. The work was performed by…

Efficient treatment of recurrent hepatitis B complications can save lives and money: NHRI researchers

970322 December 17, 2019 December 17, 2019Press Release

December 9, 2019 Scientists with Taiwan’s National Health Research Institutes (NHRI) and National Taiwan University Hospital, with the support of the Taiwan Cooperative Oncology Group (TCOG), have determined that prophylactic antiviral therapy for lymphoma patients will be essential to optimizing preventative strategies and the allocation of medical resources. In hepatitis…

970322 November 25, 2019 November 25, 2019Press Release

Frequent drinking associated with risk of head and neck cancer: NHRI study November 25, 2019 Higher frequency and amount of alcohol use are associated with an increased head and neck cancer risk, according to the results of a study conducted by the National Health Research Institutes’ National Institute of…

Do you have social jet lag? Rhythm, a new smartphone app, helps you understand your sleep rhythms

970322 November 21, 2019 November 21, 2019Press Release

November 18, 2019 A free new smartphone application, Rhythm, developed by Dr. Yu-Hsuan Lin of the National Research Health Institutes, is a breakthrough for measuring sleep patterns that can help people improve their sleep health and consequently their overall quality of life. Its features represent an important advance over what…

Substance in honeybee propolis may be useful in treating prostate cancer: new study

970322 November 21, 2019 November 21, 2019Press Release

November 11, 2019 Dysregulation of androgen receptor signaling is one of the causes promoting the development of prostate cancer, benign prostate hyperplasia (BPH), and androgenetic alopecia. The prescription drugs for these diseases either block the production of androgen or inhibit the binding between androgen and androgen receptor (AR). However,…

NHRI Taiwan launches G2020 Population Genomics Pilot, partnering with Illumina on an Operational Architecture for Population Genomics

990707 November 6, 2019 November 6, 2019Press Release

November 6, 2019 Pilot effort will sequence 10,000 genomes by end of 2020, with the goal of embedding genome sequencing in the health system by 2025. TAIPEI: The National Health Research Institutes (NHRI) of Taiwan today announced that it is taking an effort to embed whole genome and exome sequencing…

NHRI’s technology behind a novel vaccine for respiratory syncytial virus was transferred to BioChina, leading to the 2018 Outstanding Tech Transfer Award from the Ministry of Science and Technology

990707 October 24, 2019 October 24, 2019Press Release

September 2, 2019 (for immediate release) Vaccine research at the National Health Research Institutes (NHRI) of Taiwan has led to an award from the Ministry of Science and Technology for Outstanding Technology Transfer. This helps reconfirm NHRI’s essential role in Taiwan’s biomedicine sector. The technology for a novel vaccine for…

NHRI Transfers Important Biomedical Technology to OriGem for Further Development

990707 June 19, 2019 June 19, 2019Press Release

June 17, 2019 National Health Research Institutes (NHRI) of Taiwan is pleased to announce the licensing and transfer of two outstanding technologies — “A Microfluidic Dual-well Device for High-throughput Single-cell Capture and Culture” and “Selective Particle Transfer from One Device to Another” — to OriGem Biotech of Taiwan. The transfer…

NHRI licenses DBPR216, an anti-cancer developmental drug candidate, to Taivex Therapeutics Corp.

931023 April 17, 2019 April 17, 2019Press Release

April 17, 2019 The National Health Research Institutes (NHRI) and Taivex Therapeutics Corp. (Taivex) are pleased to announce the technology transfer of DBPR216, a potential anti-cancer developmental drug candidate, effective April 8. NHRI’s licensing of DBPR216, a multi-targeted tyrosine kinase inhibitor, to Taivex will further the drug’s preclinical and clinical…

Category: Press Release